ReviewThe Yale journal of biology and medicine2012
Role of microparticles in dengue virus infection and its impact on medical intervention strategies.
Review in The Yale journal of biology and medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Microparticles Released by Dengue Virus-Infected Monocytes Mediate Endothelial Activation and Vasculopathy.International journal of molecular sciences · 2026Article
- Dengue haemorrhagic fever: a job done via exosomes?Emerging microbes & infections · 2019Review
- Microparticles mediate human papillomavirus type 6 or 11 infection of human macrophages.Cellular & molecular immunology · 2017Article
- Autophagy-associated dengue vesicles promote viral transmission avoiding antibody neutralization.Scientific reports · 2016Article
- Article
- Infectious dengue vesicles derived from CD61+ cells in acute patient plasma exhibited a diaphanous appearance.Scientific reports · 2015Article
- Microparticles provide a novel biomarker to predict severe clinical outcomes of dengue virus infection.Journal of virology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue virus (DV) is one of the most important vector-borne diseases in the world. It causes a disease that manifests as a spectrum of clinical symptoms, including dengue hemorrhagic fever. DV is proficient at diverting the immune system to facilitate transmission through its vector host, Aedes spp. mosquito. Similar to other vector-borne parasites, dengue may also require a second structural form, a virus of alternative morphology (VAM), to complete its life cycle. DV can replicate to high copy numbers in patient plasma, but no classical viral particles can be detected by ultra-structural microscopy analysis. A VAM appearing as a microparticle has been recapitulated with in vitro cell lines Meg01 and K562, close relatives to the cells harboring dengue virus in vivo. VAMs are likely to contribute to the high viremia levels observed in dengue patients. This review discusses the possible existence of a VAM in the DV life cycle.
Indexed as
Identifiers
22461739PMC3313537What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.